Discovery of potent tubulin inhibitors targeting the colchicine binding site via structure-based lead optimization and antitumor evaluation

The colchicine binding site of tubulin is a promising target for discovering novel antitumour agents. Previously, we identified 2-aryl-4-amide-quinoline derivatives displayed moderate tubulin polymerisation inhibitory activity and broad-spectrum in vitro antitumour activity. In this study, structure...

Full description

Saved in:
Bibliographic Details
Published in:Journal of enzyme inhibition and medicinal chemistry 2023-12, Vol.38 (1), p.2155815-2155815
Main Authors: Liu, Wei, He, Youyou, Guo, Zhongjie, Wang, Miaomiao, Han, Xiaodong, Jia, Hairui, He, Jin, Miao, Shanshan, Wang, Shengzheng
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
antitumour activity
Binding Sites
Cancer therapies
Cell division
Cell Line, Tumor
Cell Proliferation
Clinical trials
Colchicine
Colchicine - chemistry
colchicine binding site
Drug resistance
Drug Screening Assays, Antitumor
Humans
Ligands
Metastasis
Microtubules
Molecular Structure
Motility
Pharmaceutical sciences
Pharmacy
Polymerization
Proteins
Research Paper
structural optimisation
Structure-Activity Relationship
Tubulin
Tubulin - metabolism
Tubulin inhibitors
Tubulin Modulators - chemistry
Tubulin Modulators - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c562t-d2643e3305d6b05c17658b43bbdaf577271d535e90d67450f45355d85966701e3
cites cdi_FETCH-LOGICAL-c562t-d2643e3305d6b05c17658b43bbdaf577271d535e90d67450f45355d85966701e3
container_end_page 2155815
container_issue 1
container_start_page 2155815
container_title Journal of enzyme inhibition and medicinal chemistry
container_volume 38
creator Liu, Wei
He, Youyou
Guo, Zhongjie
Wang, Miaomiao
Han, Xiaodong
Jia, Hairui
He, Jin
Miao, Shanshan
Wang, Shengzheng
description The colchicine binding site of tubulin is a promising target for discovering novel antitumour agents. Previously, we identified 2-aryl-4-amide-quinoline derivatives displayed moderate tubulin polymerisation inhibitory activity and broad-spectrum in vitro antitumour activity. In this study, structure based rational design and systematic structural optimisation were performed to obtain analogues C1∼J2 bearing diverse substituents and scaffolds. Among them, analogue G13 bearing a hydroxymethyl group displayed good tubulin polymerisation inhibitory activity (IC 50  =  13.5 μM) and potent antiproliferative activity (IC 50 values: 0.65 μM∼0.90 μM). G13 potently inhibited the migration and invasion of MDA-MB-231 cells, and displayed potent antiangiogenic activity. It efficiently increased intracellular ROS level and decreased MMP in cancer cells, and obviously induced the fragmentation and disassembly of the microtubules network. More importantly, G13 exhibited good in vivo antitumour efficacy in MDA-MB-231 xenograft model (TGI  =  38.2%; i.p., 30 mg/kg).
doi_str_mv 10.1080/14756366.2022.2155815
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2917561428</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_1ee17a3b8c554a94a78f1efbb7b57ebb</doaj_id><sourcerecordid>2917561428</sourcerecordid><originalsourceid>FETCH-LOGICAL-c562t-d2643e3305d6b05c17658b43bbdaf577271d535e90d67450f45355d85966701e3</originalsourceid><addsrcrecordid>eNp9UstuEzEUHSEQLYVPAFliwybB9vgxs0FU5VWpEhtYW37cSVzN2MH2BIVf4KdxmjSiLFhY9j333GPf69M0LwleEtzht4RJLlohlhRTuqSE847wR835Hl-IVrLHp7MQZ82znG8xpoQS9rQ5qxDtGW3Pm98ffLZxC2mH4oA2sUAoqMxmHn1APqy98SWmjIpOKyg-rFBZA7JxtGtvfQBkfHB7OPsCaOs1yiXNtswJFkZncGgE7VDcFD_5X7r4GJAOrq7iyzzFhGCrx_ku8bx5Mugxw4vjftF8__Tx29WXxc3Xz9dXlzcLywUtC0cFa6FtMXfCYG6JFLwzrDXG6YFLSSVxvOXQYyck43hgNeKu470QEhNoL5rrg66L-lZtkp902qmovboDYlopnYq3IygCQKRuTWc5Z7pnWnYDgcEYabgEY6rWu4PWZjYTOFvHl_T4QPRhJvi1WsWt6jvWtRxXgTdHgRR_zJCLmuqPwDjqAHHOikrBGKs99pX6-h_qbZxTqKNStCfVDoTRrrL4gWVTzDnBcHoMwWpvHXVvHbW3jjpap9a9-ruTU9W9Vyrh_YHgwxDTpH_GNDpV9G6MaUg6WJ9V-_87_gDMXNZi</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2917561428</pqid></control><display><type>article</type><title>Discovery of potent tubulin inhibitors targeting the colchicine binding site via structure-based lead optimization and antitumor evaluation</title><source>Taylor &amp; Francis</source><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Liu, Wei ; He, Youyou ; Guo, Zhongjie ; Wang, Miaomiao ; Han, Xiaodong ; Jia, Hairui ; He, Jin ; Miao, Shanshan ; Wang, Shengzheng</creator><creatorcontrib>Liu, Wei ; He, Youyou ; Guo, Zhongjie ; Wang, Miaomiao ; Han, Xiaodong ; Jia, Hairui ; He, Jin ; Miao, Shanshan ; Wang, Shengzheng</creatorcontrib><description>The colchicine binding site of tubulin is a promising target for discovering novel antitumour agents. Previously, we identified 2-aryl-4-amide-quinoline derivatives displayed moderate tubulin polymerisation inhibitory activity and broad-spectrum in vitro antitumour activity. In this study, structure based rational design and systematic structural optimisation were performed to obtain analogues C1∼J2 bearing diverse substituents and scaffolds. Among them, analogue G13 bearing a hydroxymethyl group displayed good tubulin polymerisation inhibitory activity (IC 50  =  13.5 μM) and potent antiproliferative activity (IC 50 values: 0.65 μM∼0.90 μM). G13 potently inhibited the migration and invasion of MDA-MB-231 cells, and displayed potent antiangiogenic activity. It efficiently increased intracellular ROS level and decreased MMP in cancer cells, and obviously induced the fragmentation and disassembly of the microtubules network. More importantly, G13 exhibited good in vivo antitumour efficacy in MDA-MB-231 xenograft model (TGI  =  38.2%; i.p., 30 mg/kg).</description><identifier>ISSN: 1475-6366</identifier><identifier>EISSN: 1475-6374</identifier><identifier>DOI: 10.1080/14756366.2022.2155815</identifier><identifier>PMID: 36629423</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>Animals ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; antitumour activity ; Binding Sites ; Cancer therapies ; Cell division ; Cell Line, Tumor ; Cell Proliferation ; Clinical trials ; Colchicine ; Colchicine - chemistry ; colchicine binding site ; Drug resistance ; Drug Screening Assays, Antitumor ; Humans ; Ligands ; Metastasis ; Microtubules ; Molecular Structure ; Motility ; Pharmaceutical sciences ; Pharmacy ; Polymerization ; Proteins ; Research Paper ; structural optimisation ; Structure-Activity Relationship ; Tubulin ; Tubulin - metabolism ; Tubulin inhibitors ; Tubulin Modulators - chemistry ; Tubulin Modulators - pharmacology</subject><ispartof>Journal of enzyme inhibition and medicinal chemistry, 2023-12, Vol.38 (1), p.2155815-2155815</ispartof><rights>2023 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2023</rights><rights>2023 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. This work is licensed under the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 The Author(s). Published by Informa UK Limited, trading as Taylor &amp; Francis Group. 2023 The Author(s)</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c562t-d2643e3305d6b05c17658b43bbdaf577271d535e90d67450f45355d85966701e3</citedby><cites>FETCH-LOGICAL-c562t-d2643e3305d6b05c17658b43bbdaf577271d535e90d67450f45355d85966701e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848350/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2917561428?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27502,27924,27925,37012,37013,44590,53791,53793,59143,59144</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36629423$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Liu, Wei</creatorcontrib><creatorcontrib>He, Youyou</creatorcontrib><creatorcontrib>Guo, Zhongjie</creatorcontrib><creatorcontrib>Wang, Miaomiao</creatorcontrib><creatorcontrib>Han, Xiaodong</creatorcontrib><creatorcontrib>Jia, Hairui</creatorcontrib><creatorcontrib>He, Jin</creatorcontrib><creatorcontrib>Miao, Shanshan</creatorcontrib><creatorcontrib>Wang, Shengzheng</creatorcontrib><title>Discovery of potent tubulin inhibitors targeting the colchicine binding site via structure-based lead optimization and antitumor evaluation</title><title>Journal of enzyme inhibition and medicinal chemistry</title><addtitle>J Enzyme Inhib Med Chem</addtitle><description>The colchicine binding site of tubulin is a promising target for discovering novel antitumour agents. Previously, we identified 2-aryl-4-amide-quinoline derivatives displayed moderate tubulin polymerisation inhibitory activity and broad-spectrum in vitro antitumour activity. In this study, structure based rational design and systematic structural optimisation were performed to obtain analogues C1∼J2 bearing diverse substituents and scaffolds. Among them, analogue G13 bearing a hydroxymethyl group displayed good tubulin polymerisation inhibitory activity (IC 50  =  13.5 μM) and potent antiproliferative activity (IC 50 values: 0.65 μM∼0.90 μM). G13 potently inhibited the migration and invasion of MDA-MB-231 cells, and displayed potent antiangiogenic activity. It efficiently increased intracellular ROS level and decreased MMP in cancer cells, and obviously induced the fragmentation and disassembly of the microtubules network. More importantly, G13 exhibited good in vivo antitumour efficacy in MDA-MB-231 xenograft model (TGI  =  38.2%; i.p., 30 mg/kg).</description><subject>Animals</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>antitumour activity</subject><subject>Binding Sites</subject><subject>Cancer therapies</subject><subject>Cell division</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation</subject><subject>Clinical trials</subject><subject>Colchicine</subject><subject>Colchicine - chemistry</subject><subject>colchicine binding site</subject><subject>Drug resistance</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Humans</subject><subject>Ligands</subject><subject>Metastasis</subject><subject>Microtubules</subject><subject>Molecular Structure</subject><subject>Motility</subject><subject>Pharmaceutical sciences</subject><subject>Pharmacy</subject><subject>Polymerization</subject><subject>Proteins</subject><subject>Research Paper</subject><subject>structural optimisation</subject><subject>Structure-Activity Relationship</subject><subject>Tubulin</subject><subject>Tubulin - metabolism</subject><subject>Tubulin inhibitors</subject><subject>Tubulin Modulators - chemistry</subject><subject>Tubulin Modulators - pharmacology</subject><issn>1475-6366</issn><issn>1475-6374</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>0YH</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp9UstuEzEUHSEQLYVPAFliwybB9vgxs0FU5VWpEhtYW37cSVzN2MH2BIVf4KdxmjSiLFhY9j333GPf69M0LwleEtzht4RJLlohlhRTuqSE847wR835Hl-IVrLHp7MQZ82znG8xpoQS9rQ5qxDtGW3Pm98ffLZxC2mH4oA2sUAoqMxmHn1APqy98SWmjIpOKyg-rFBZA7JxtGtvfQBkfHB7OPsCaOs1yiXNtswJFkZncGgE7VDcFD_5X7r4GJAOrq7iyzzFhGCrx_ku8bx5Mugxw4vjftF8__Tx29WXxc3Xz9dXlzcLywUtC0cFa6FtMXfCYG6JFLwzrDXG6YFLSSVxvOXQYyck43hgNeKu470QEhNoL5rrg66L-lZtkp902qmovboDYlopnYq3IygCQKRuTWc5Z7pnWnYDgcEYabgEY6rWu4PWZjYTOFvHl_T4QPRhJvi1WsWt6jvWtRxXgTdHgRR_zJCLmuqPwDjqAHHOikrBGKs99pX6-h_qbZxTqKNStCfVDoTRrrL4gWVTzDnBcHoMwWpvHXVvHbW3jjpap9a9-ruTU9W9Vyrh_YHgwxDTpH_GNDpV9G6MaUg6WJ9V-_87_gDMXNZi</recordid><startdate>202312</startdate><enddate>202312</enddate><creator>Liu, Wei</creator><creator>He, Youyou</creator><creator>Guo, Zhongjie</creator><creator>Wang, Miaomiao</creator><creator>Han, Xiaodong</creator><creator>Jia, Hairui</creator><creator>He, Jin</creator><creator>Miao, Shanshan</creator><creator>Wang, Shengzheng</creator><general>Taylor &amp; Francis</general><general>Taylor &amp; Francis Ltd</general><general>Taylor &amp; Francis Group</general><scope>0YH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>202312</creationdate><title>Discovery of potent tubulin inhibitors targeting the colchicine binding site via structure-based lead optimization and antitumor evaluation</title><author>Liu, Wei ; He, Youyou ; Guo, Zhongjie ; Wang, Miaomiao ; Han, Xiaodong ; Jia, Hairui ; He, Jin ; Miao, Shanshan ; Wang, Shengzheng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c562t-d2643e3305d6b05c17658b43bbdaf577271d535e90d67450f45355d85966701e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>antitumour activity</topic><topic>Binding Sites</topic><topic>Cancer therapies</topic><topic>Cell division</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation</topic><topic>Clinical trials</topic><topic>Colchicine</topic><topic>Colchicine - chemistry</topic><topic>colchicine binding site</topic><topic>Drug resistance</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Humans</topic><topic>Ligands</topic><topic>Metastasis</topic><topic>Microtubules</topic><topic>Molecular Structure</topic><topic>Motility</topic><topic>Pharmaceutical sciences</topic><topic>Pharmacy</topic><topic>Polymerization</topic><topic>Proteins</topic><topic>Research Paper</topic><topic>structural optimisation</topic><topic>Structure-Activity Relationship</topic><topic>Tubulin</topic><topic>Tubulin - metabolism</topic><topic>Tubulin inhibitors</topic><topic>Tubulin Modulators - chemistry</topic><topic>Tubulin Modulators - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Liu, Wei</creatorcontrib><creatorcontrib>He, Youyou</creatorcontrib><creatorcontrib>Guo, Zhongjie</creatorcontrib><creatorcontrib>Wang, Miaomiao</creatorcontrib><creatorcontrib>Han, Xiaodong</creatorcontrib><creatorcontrib>Jia, Hairui</creatorcontrib><creatorcontrib>He, Jin</creatorcontrib><creatorcontrib>Miao, Shanshan</creatorcontrib><creatorcontrib>Wang, Shengzheng</creatorcontrib><collection>Taylor &amp; Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Journal of enzyme inhibition and medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Liu, Wei</au><au>He, Youyou</au><au>Guo, Zhongjie</au><au>Wang, Miaomiao</au><au>Han, Xiaodong</au><au>Jia, Hairui</au><au>He, Jin</au><au>Miao, Shanshan</au><au>Wang, Shengzheng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discovery of potent tubulin inhibitors targeting the colchicine binding site via structure-based lead optimization and antitumor evaluation</atitle><jtitle>Journal of enzyme inhibition and medicinal chemistry</jtitle><addtitle>J Enzyme Inhib Med Chem</addtitle><date>2023-12</date><risdate>2023</risdate><volume>38</volume><issue>1</issue><spage>2155815</spage><epage>2155815</epage><pages>2155815-2155815</pages><issn>1475-6366</issn><eissn>1475-6374</eissn><abstract>The colchicine binding site of tubulin is a promising target for discovering novel antitumour agents. Previously, we identified 2-aryl-4-amide-quinoline derivatives displayed moderate tubulin polymerisation inhibitory activity and broad-spectrum in vitro antitumour activity. In this study, structure based rational design and systematic structural optimisation were performed to obtain analogues C1∼J2 bearing diverse substituents and scaffolds. Among them, analogue G13 bearing a hydroxymethyl group displayed good tubulin polymerisation inhibitory activity (IC 50  =  13.5 μM) and potent antiproliferative activity (IC 50 values: 0.65 μM∼0.90 μM). G13 potently inhibited the migration and invasion of MDA-MB-231 cells, and displayed potent antiangiogenic activity. It efficiently increased intracellular ROS level and decreased MMP in cancer cells, and obviously induced the fragmentation and disassembly of the microtubules network. More importantly, G13 exhibited good in vivo antitumour efficacy in MDA-MB-231 xenograft model (TGI  =  38.2%; i.p., 30 mg/kg).</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>36629423</pmid><doi>10.1080/14756366.2022.2155815</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1475-6366
ispartof Journal of enzyme inhibition and medicinal chemistry, 2023-12, Vol.38 (1), p.2155815-2155815
issn 1475-6366
1475-6374
language eng
recordid cdi_proquest_journals_2917561428
source Taylor & Francis; Publicly Available Content Database; PubMed Central
subjects Animals
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
antitumour activity
Binding Sites
Cancer therapies
Cell division
Cell Line, Tumor
Cell Proliferation
Clinical trials
Colchicine
Colchicine - chemistry
colchicine binding site
Drug resistance
Drug Screening Assays, Antitumor
Humans
Ligands
Metastasis
Microtubules
Molecular Structure
Motility
Pharmaceutical sciences
Pharmacy
Polymerization
Proteins
Research Paper
structural optimisation
Structure-Activity Relationship
Tubulin
Tubulin - metabolism
Tubulin inhibitors
Tubulin Modulators - chemistry
Tubulin Modulators - pharmacology
title Discovery of potent tubulin inhibitors targeting the colchicine binding site via structure-based lead optimization and antitumor evaluation
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T20%3A27%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discovery%20of%20potent%20tubulin%20inhibitors%20targeting%20the%20colchicine%20binding%20site%20via%20structure-based%20lead%20optimization%20and%20antitumor%20evaluation&rft.jtitle=Journal%20of%20enzyme%20inhibition%20and%20medicinal%20chemistry&rft.au=Liu,%20Wei&rft.date=2023-12&rft.volume=38&rft.issue=1&rft.spage=2155815&rft.epage=2155815&rft.pages=2155815-2155815&rft.issn=1475-6366&rft.eissn=1475-6374&rft_id=info:doi/10.1080/14756366.2022.2155815&rft_dat=%3Cproquest_cross%3E2917561428%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c562t-d2643e3305d6b05c17658b43bbdaf577271d535e90d67450f45355d85966701e3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2917561428&rft_id=info:pmid/36629423&rfr_iscdi=true